Themis Medicare Ltd Stock Price Today (NSE: THEMISMED)
Fundamental Score
Themis Medicare Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Themis Medicare Ltd share price today is ₹91.04, up +0.00% on NSE/BSE as of 17 February 2026. Themis Medicare Ltd (THEMISMED) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹969.87 (Cr). The 52-week high for THEMISMED share price is ₹N/A and the 52-week low is ₹N/A. The company has a Return on Equity (ROE) of 7.65% and a debt-to-equity ratio of 0.25.
Themis Medicare Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Themis Medicare Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Themis Medicare Share Price: A ROCE-Focused Analysis
The pharmaceutical sector is currently experiencing a period of nuanced growth, driven by increasing healthcare awareness and aging populations, but also facing pressures from generic competition and evolving regulatory landscapes. This analysis examines the current trading price of ₹83.68 for Themis Medicare Ltd, focusing primarily on its Return on Capital Employed (ROCE) and comparative performance against its peers. This analysis is part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra.
A crucial metric for evaluating a company's efficiency in deploying capital is its ROCE. Themis Medicare Ltd presents a ROCE of 10.37%. This figure provides insights into how effectively the company generates profit from its capital investments, including both debt and equity. A higher ROCE typically signifies a more efficient use of capital and potentially a stronger competitive moat. In Themis Medicare's case, this level of ROCE suggests a moderate degree of operational efficiency. The impact of this ROCE contributes to a sustainable performance in the long run.
However, it's important to contextualize this ROCE within the broader industry. Compared to peers such as Mankind Pharma Ltd, Smruthi Organics Ltd, and Balaxi Pharmaceuticals Ltd, Themis Medicare’s relative standing needs further investigation. While direct comparison requires access to current ROCE figures for these specific peers, we can make general observations. Companies with consistently high ROCE figures, such as
Mankind Pharma Ltd, often demonstrate superior management quality capable of consistently generating higher returns on invested capital.Ultimately, Themis Medicare's 10.37% ROCE suggests a reasonable level of capital efficiency. It underscores the importance of ongoing monitoring and comparison with industry benchmarks to assess the long-term sustainability of its business model. Further analysis, encompassing factors beyond ROCE, such as debt levels, revenue growth, and pipeline strength, are essential for a complete evaluation. This analysis is purely observational and does not constitute investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Themis Medicare Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of THEMISMED across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Operating Margins (17.72%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Consistent Growth Track Record (15.00% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Conservative Debt Levels (D/E: 0.25)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Cash Generation (₹66.09 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (67.15%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
7 factors identified
Below-Average Return on Equity (7.65%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Profit Decline Concern (-125.33%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-33.35%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Weak Earnings Growth (3.88% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (3.91% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (-1.58x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 0.07%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Themis Medicare Ltd Financial Statements
Comprehensive financial data for Themis Medicare Ltd including income statement, balance sheet and cash flow
About THEMISMED (Themis Medicare Ltd)
Themis Medicare Ltd (THEMISMED) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹969.87 (Cr). Themis Medicare Ltd has delivered a Return on Equity (ROE) of 7.65% and a ROCE of 10.37%. The debt-to-equity ratio stands at 0.25, reflecting the company's capital structure. Investors tracking THEMISMED share price can monitor key metrics including P/E ratio, promoter holding of 67.15%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
THEMISMED Share Price: Frequently Asked Questions
What is the current share price of Themis Medicare Ltd (THEMISMED)?
As of 17 Feb 2026, 10:25 am IST, Themis Medicare Ltd share price is ₹91.04. The THEMISMED stock has a market capitalisation of ₹969.87 (Cr) on NSE/BSE.
Is THEMISMED share price Overvalued or Undervalued?
THEMISMED share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the Themis Medicare Ltd stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of THEMISMED share price?
The 52-week high of THEMISMED share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Themis Medicare Ltd share price?
Key factors influencing THEMISMED share price include quarterly earnings growth (Sales Growth: -33.35%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Themis Medicare Ltd a good stock for long-term investment?
Themis Medicare Ltd shows a 5-year Profit Growth of 3.91% and an ROE of 7.65%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.25 before investing in THEMISMED shares.
How does Themis Medicare Ltd compare with its industry peers?
Themis Medicare Ltd competes with major peers in the Pharmaceuticals. Investors should compare THEMISMED share price P/E of 0.00x and ROE of 7.65% against the industry averages to determine competitive standing.
What is the P/E ratio of THEMISMED and what does it mean?
THEMISMED share price has a P/E ratio of N/Ax compared to the industry average of 31.77x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is THEMISMED performing according to Bull Run's analysis?
THEMISMED has a Bull Run fundamental score of 30/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does THEMISMED belong to?
THEMISMED operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Themis Medicare Ltd share price.
What is Return on Equity (ROE) and why is it important for THEMISMED?
THEMISMED has an ROE of 7.65%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Themis Medicare Ltd generates profits from shareholders capital.
How is THEMISMED debt-to-equity ratio and what does it indicate?
THEMISMED has a debt-to-equity ratio of 0.25, which indicates conservative financing with low financial risk.
What is THEMISMED dividend yield and is it a good dividend stock?
THEMISMED offers a dividend yield of 0.48%, meaning you receive ₹0.48 annual dividend for every ₹100 invested in Themis Medicare Ltd shares.
How has THEMISMED share price grown over the past 5 years?
THEMISMED has achieved 5-year growth rates of: Sales Growth 15.00%, Profit Growth 3.91%, and EPS Growth 3.88%.
What is the promoter holding in THEMISMED and why does it matter?
Promoters hold 67.15% of THEMISMED shares, with 2.43% pledged. High promoter holding often indicates strong management confidence in Themis Medicare Ltd.
What is THEMISMED market capitalisation category?
THEMISMED has a market capitalisation of ₹970 crores, placing it in the Small-cap category.
How volatile is THEMISMED stock?
THEMISMED has a beta of N/A. A beta > 1 suggests the Themis Medicare Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is THEMISMED operating profit margin trend?
THEMISMED has a 5-year average Operating Profit Margin (OPM) of 17.72%, indicating the company's operational efficiency.
How is THEMISMED quarterly performance?
Recent quarterly performance shows Themis Medicare Ltd YoY Sales Growth of -33.35% and YoY Profit Growth of -125.33%.
What is the institutional holding pattern in THEMISMED?
THEMISMED has FII holding of 0.06% and DII holding of 0.01%. Significant institutional holding often suggests professional confidence in the Themis Medicare Ltd stock.